Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Intangibles (2023 - 2025)

Rein Therapeutics (RNTX) has disclosed Intangibles for 3 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 68.01% to $13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Dec 2025, down 68.01% year-over-year, with the annual reading at $13.5 million for FY2025, 68.01% down from the prior year.
  • Intangibles for Q4 2025 was $13.5 million at Rein Therapeutics, down from $42.2 million in the prior quarter.
  • The five-year high for Intangibles was $79.2 million in Q4 2023, with the low at $13.5 million in Q4 2025.
  • Average Intangibles over 3 years is $55.5 million, with a median of $42.2 million recorded in 2024.
  • The sharpest move saw Intangibles crashed 46.72% in 2024, then crashed 68.01% in 2025.
  • Over 3 years, Intangibles stood at $79.2 million in 2023, then plummeted by 46.72% to $42.2 million in 2024, then tumbled by 68.01% to $13.5 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $13.5 million, $42.2 million, and $42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.